Summary and next episodes
In this conference update video, Prof. Shaheenah Dawood joins us from ASCO 2024 to share her insights into new key breast cancer trial data from the DESTINY-Breast06, postMONARCH and INAVO120 trials and the potential impact on clinical practice.
ASCO 2024 selected breast cancer abstracts
- Trastuzumab deruxtecan vs physician’s choice of chemotherapy in patients with HR+, HER2-low or HER2-ultralow metastatic breast cancer with prior endocrine therapy: Primary results from DESTINY-Breast06 (DB-06).
Curigliano G, et al.
Abstract LBA1000, ASCO 2024 - Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
Kalinsky K, et al.
Abstract LBA1001, ASCO 2024 - First-line inavolisib/placebo + palbociclib + fulvestrant in patients with PIK3CA-mutated, HR+, HER2‑negative locally advanced/metastatic breast cancer who relapsed during/within 12 months of adjuvant endocrine therapy completion: INAVO120 Phase 3 randomized trial additional analyses.
Juric D, et al.
Abstract #1003, ASCO 2024
Duration
Language(s)
Downloadable 
25 MIN
Dec 2025 
